From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weight loss jabs

The Business Journal noted rising demand for these drugs, while Muscle & Fitness highlighted a new meta‑analysis on muscle loss. The breadth of coverage shows how the market and health community are confronting both hype and science. The Wall Street Journal explored cases where patients use GLP‑1s for reasons other than weight loss, and Medscape asked whether statins retain relevance alongside the new therapy. Runner’s World warned that runners can use GLP‑1s safely if they monitor injury risk factors, while SciTechDaily examined which body components actually disappear during drug‑induced weight loss.

Together these pieces map a shifting narrative from pure slimming to broader health considerations. South Korean daily 매일경제 declared that the worldwide craze for obesity‑injection drugs is “useless,” echoing a Baton Rouge specialist’s comment in WBRZ that GLP‑1s may not work for everyone. The Business Journal’s note on compounded alternatives gaining ground suggests a market response to efficacy doubts. These divergent viewpoints underscore that clinicians and consumers are still weighing the real‑world performance of GLP‑1s against expectations set by early hype.

Future coverage will need to track clinical trials cited by Medscape and the meta‑analysis referenced by Muscle & Fitness, as well as any regulatory reviews of compounded GLP‑1 products noted by the Business Journal. How insurers respond to mixed efficacy claims, such as those from WBRZ and 매일경제, will also shape market momentum.